MIT team builds low-cost cancer urine test; Munich group creates MS test that works before symptoms appear;

> Engineers at MIT have come up with a low-cost urine test for cancer. Item

> Alberto Gutierrez, director of the FDA's Office of In Vitro Diagnostics in the Center for Devices and Radiological Health, will discuss the agency's guidance on in vitro diagnostic products for research use only or investigational use only during a Feb. 26 webinar hosted by the American Association for Clinical Chemistry. Item

> Researchers have found that combining Mutant-Allele Tumor Heterogeneity as a biomarker with a patient's HPV status can give an effective indicator of improved patient outcome in head and neck squamous cell carcinoma. Item

> Researchers at the Technical University of Munich came up with a blood test designed to help identify multiple sclerosis before any symptoms show up. Item

> A team of doctors and engineers is using computational modeling to build a quicker, less-expensive way to help spot prostate cancer. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.